The AI Boom Has Triggered a Shortage of Lab Monkeys

AI and the Pharmaceutical Crisis

The rapid advancement of artificial intelligence (AI) in medicine has created an unexpected dilemma. The discovery and testing of new drugs have accelerated so significantly that the demand for laboratory monkeys, specifically macaques, has reached a critical point. This trend is clearly reflected in market prices: while a single macaque cost approximately $3,000 in 2019, today the price exceeds $20,000.

In response to this crisis, Palantir co-founder Joe Lonsdale has backed the startup Safer Human Medicine. The company plans to establish a large-scale breeding facility in the US, aiming to raise up to 30,000 monkeys over the next 20 years. The project's goal is to make the US pharmaceutical industry independent of international imports.

China’s Export Ban and Supply Chains

The problem began before the recent AI surge. Until 2020, China was the primary supplier for US laboratories, controlling approximately 60% of the market. After China officially banned exports, American researchers sought alternative sources, including Cambodia. However, this process ended in scandal in 2022, following reports that wild-caught monkeys were being supplied to labs with falsified documents claiming they were captive-bred.

Currently, US laboratories require approximately 20,000 monkeys annually. Safer Human Medicine plans to initially import 500 to 1,000 individuals from existing farms in Asia to begin local breeding. However, biological constraints present a significant challenge: female macaques reach sexual maturity at four years of age and produce only one offspring per year, making rapid population growth physically impossible.

Ethical Debates and Future Outlook

The project has already drawn sharp criticism from animal rights advocates. Numerous calls have circulated on social media labeling the construction of such a farm as "morally unjustifiable." Some activists are attempting to halt such initiatives through legal channels, which could significantly damage or delay the company's plans.

For regions like Georgia, where the pharmaceutical sector and biotechnological research are gradually developing, this issue is significant because fluctuations in the global supply chain directly affect the cost of drug production. If the deficit in the US market persists, it will further increase the costs of researching and implementing new-generation drugs, ultimately impacting global patient access.